KetoSwiss AG
- 14/08/2023
- Pre Series A
- $4,800,000
KetoSwiss is a Swiss biotechnology company located in Basel, that develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolic dysfunction (such as Alzheimer's disease). The lead product’s active substance is an endogenous metabolite – a Ketone body, that can be used by the human brain as an alternative source of fuel to glucose, when glucose utilization or transport is compromised.
- Industry Biotechnology
- Website https://www.keto.swiss/
- LinkedIn https://www.linkedin.com/company/ketoswiss/about/
Related People
Elena GrossFounder
Elena holds an MSc in Neuroscience (University of Oxford) and a PhD in clinical research (Dr sc. med; University of Basel, Switzerland). She is also an ex chronic migraine patient. Frustrated by the available treatment options for migraines, her research career has focused on better understanding this common and debilitating disease, with the ultimate goal on improving clinical care. Elena is particularly passionate about the therapeutic benefits of ketosis and other nutritional interventions, mitochondrial functioning and energy metabolism, brain health and neurological diseases (migraines in particular) and increasing health span via disease prevention.
Her start-up KetoSwiss has been awarded several prizes, she has publications in high-ranking journals (such as Nature Neurology) and she is the inventor of three patents.
Elena is also the founder and CEO of KetoSwiss, a Swiss biotech startup that develops medical foods for the dietary management of neuro/psychiatric diseases, with a focus of improving brain energetics under the "brain ritual" brand. Its mission is to provide an effective solution to neuro/psychiatric diseases (starting with MigraKet for migraine) without the side effects of classical pharma products, based on solid scientific research and inspired by evolution.